U.S. Securities and Exchange Commission
Washington, D.C. 20549
Form 10-QSB/A
(Mark One)
[X] QUARTERLY REPORT PURSUANT SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 1996
[ ] TRANSITION REPORT PURSUANT SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to
Commission file number 33-36120
BRADLEY PHARMACEUTICALS, INC.
(Exact name of small business issuer as
specified in its charter)
New Jersey 22-2581418
(State or other jurisdiction (IRS Employer
of incorporation or organization) Identification No.)
383 Route 46 W., Fairfield, NJ
(Address of principal executive offices)
201-882-1505
(Issuer's telephone number)
(Former name, former address and former fiscal year, if changed since
last report)
Check whether the issuer (1) filed all reports required to be filed by
section 13 or
15(d) of the Exchange Act during the past 12 months (or for such
shorter period that
the registrant was required to file such reports), and (2) has been subject
to such filing
requirements for the past 90 days. Yes No
State the number of shares outstanding of each of the issuer's classes
of common
equity, as of the latest practicable date:
Title of Each Class Number of Shares Outstanding
of Common Stock as of November 8, 1996
Class A, No Par Value 6,692,267
Class B, No Par Value 431,552
Transitional Small Business Disclosure Format (check one):
Yes No
SIGNATURES
In accordance with the requirement of the Exchange Act, the Registrant
caused this report
to be signed on its behalf by the undersigned, thereunto duly authorized.
BRADLEY PHARMACEUTICALS, INC.
(REGISTRANT)
Date: November 13, 1996 /s/ Daniel Glassman
Daniel Glassman
Chairman of the Board, President and
Chief Executive Officer
(Principal Executive Officer)
Date: November 13, 1996 /s/ Alan V. Gallantar
Alan V. Gallantar
Corporate Vice President and
Chief Financial Officer
(Principal Financial and Accounting
Officer)
<TABLE> <S> <C>
<ARTICLE> 5
<LEGEND>
This schedule contains summary financial information extracted from Balance
Sheet, Cash Flow and Statement of Operations and is qualified in its entirety
by reference to such financial statements.
</LEGEND>
<CIK> 0000864268
<NAME> FDS3Q
<S> <C>
<PERIOD-TYPE> 9-MOS
<FISCAL-YEAR-END> DEC-31-1996
<PERIOD-END> SEP-30-1996
<CASH> 11522
<SECURITIES> 0
<RECEIVABLES> 824562
<ALLOWANCES> 107657
<INVENTORY> 1466345
<CURRENT-ASSETS> 5895063
<PP&E> 1249832
<DEPRECIATION> 843826
<TOTAL-ASSETS> 23908707
<CURRENT-LIABILITIES> 8823028
<BONDS> 4743031
0
0
<COMMON> 13615813
<OTHER-SE> (3273165)
<TOTAL-LIABILITY-AND-EQUITY> 23908707
<SALES> 9052940
<TOTAL-REVENUES> 9052940
<CGS> 2308619
<TOTAL-COSTS> 2308619
<OTHER-EXPENSES> 0
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 476297
<INCOME-PRETAX> 1475828
<INCOME-TAX> 150000
<INCOME-CONTINUING> 1325828
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 1325828
<EPS-PRIMARY> .18
<EPS-DILUTED> .18
</TABLE>
